Testim 1 Gel: Review of Clinical Data
|
|
- Lorena O’Brien’
- 5 years ago
- Views:
Transcription
1 European Urology Supplements European Urology Supplements 4 (2005) Testim 1 Gel: Review of Clinical Data Tom A. McNicholas* Department of Urology, Lister Hospital, Corey s Mill Lane, Stevenage, Hertfordshire SG1 4AB, UK Abstract Late-onset hypogonadism is a medical condition characterized by testosterone deficiency in ageing men, accompanied by clinical symptoms, that can negatively affect quality of life and multiple organ systems. The condition is generally managed using testosterone substitution. Many formulations of testosterone are available, including deep-muscle injections, buccal formulations, transdermal patches, and topical gels. Testim 1 Gel 1% testosterone gel (Auxilium Pharmaceuticals Norristown, Pennsylvania, USA, and Ipsen Paris, France) has been shown to restore serum testosterone concentrations to within the normal range in men with hypogonadism. Two randomized, controlled studies showed that Testim 1 Gel significantly improved sexual motivation, desire, performance, and function, as well as positive and negative mood scores and body composition after 90 days, compared with baseline. The magnitude of improvement seen with Testim 1 Gel was similar to that achieved with testosterone patches, but with fewer application-site reactions. Improvements in mood and sexual function were seen within the first 2 weeks of treatment. Long-term, open-label extension studies of Testim 1 Gel suggest that clinical benefits are maintained for up to 12 months without an additional increase in side-effects. Notably, Testim 1 Gel treatment for 12 months was associated with a gradual increase in bone mineral density, suggesting that Testim 1 Gel may help to prevent osteoporosis. The most common adverse events associated with Testim 1 Gel were application-site reactions, increased haematological parameters, and moderately increased prostate-specific antigen levels that remained within the normal range. Overall, the clinical evidence indicates that Testim 1 Gel is a safe and effective treatment option for use in the management of male hypogonadism. # 2005 Elsevier B.V. All rights reserved. Keywords: Hypogonadism; Late-onset hypogonadism; Testosterone; Testosterone gel; Testim Gel 1. Introduction * Tel ; Fax: address: mcnic@globalnet.co.uk. Late-onset hypogonadism (LOH) is a clinical and biochemical condition associated with advancing age that is characterized by testosterone deficiency with or without reduced genomic sensitivity to testosterone [1]. If left unmanaged, LOH can negatively affect the function of multiple organ systems and impair quality of life in older men. LOH is managed primarily with testosterone substitution, the goals of which are: to restore testosterone levels to within the normal range; stimulate and maintain virilization (e.g. secondary sex characteristics, such as muscle mass, fat distribution, body hair); optimize bone density and prevent osteoporosis; potentially reduce cardiovascular risk; and restore sexual function, libido, and well-being [1]. Ideally, these goals should be met reliably, safely, and conveniently. Several formulations of testosterone are currently available for the treatment of hypogonadism, including intramuscular injections, buccal formulations, transdermal patches, and topical gels. Testim 1 Gel 1% testosterone gel (Auxilium Pharmaceuticals Norristown, Pennsylvania, USA, and Ipsen Paris, France) is a fast-drying topical gel that is available in Europe and the USA for the treatment of male hypogonadism. One 5 g tube of Testim 1 Gel contains 50 mg of testosterone. Application of 1 or 2 tubes daily to the shoulders or upper arms has been shown to restore average serum testosterone levels to within the normal range ( nmol/l or ng/dl) in men with hypogonadism [2]. This paper reviews the clinical evidence available on the use of Testim 1 Gel in the management /$ see front matter # 2005 Elsevier B.V. All rights reserved. doi: /j.eursup
2 of men with hypogonadism [2 6]. An overview of the clinical trials that will be discussed is given in Table 1 [2 6]. T.A. McNicholas / European Urology Supplements 4 (2005) Pharmacokinetics Marbury et al. [2] compared the pharmacokinetic profile of Testim 1 Gel with that of another commercially available testosterone gel (AndroGel 1 /Testogel 1 Unimed Pharmaceuticals, Inc., and Solvay Pharmaceuticals, Inc., Marietta, Georgia, USA). A total of 29 men with hypogonadism aged >45 years were given a single administration of each gel (50 mg) 7 days apart [2]. Blood samples were taken regularly during the 24- hour period following application and again at 48 hours [2]. At baseline, 19 patients had a morning serum testosterone concentration <8.675 nmol/l and 10 had a concentration nmol/l [2]. In general, mean concentrations of serum testosterone were higher following Testim 1 Gel administration, compared with AndroGel 1 /Testogel 1 (Fig. 1) [2]. Geometric mean estimates of the peak serum concentration (C max )and the 24-hour systemic availability (AUC 0 24 ) were also consistently higher following Testim 1 Gel administration (C max : 480 ng/ml vs. 368 ng/ml; AUC 0 24 : 5865 ngh/dl vs ngh/dl) [2]. The ratio of the treatment comparison was 1.30 (90% CI ) for C max and 1.30 (90% CI ) for AUC 0 24,indicating that Testim 1 Gel and AndroGel 1 /Testogel 1 are Fig. 1. Total serum testosterone levels over 48 hours following a single dose of Testim 1 Gel 50 mg or AndroGel 1 /Testogel 1 50 mg (N =29)[2].(Reproduced with permission [2]. Copyright# 2003 John Wiley and Sons Ltd.). not bioequivalent [2]. Similar findings were found when serum concentrations of dihydrotestosterone (DHT) and free testosterone were compared following each treatment [2]. Testim 1 Gel may also have a favourable pharmacokinetic profile when compared with testosterone patches. Two randomized, controlled trials collected pharmacokinetic data after 90 days of treatment with Testim 1 Gel (50 mg or 100 mg daily) or a testosterone patch (Andropatch 1 [GlaxoSmithKline Brentford, UK] or Androderm 1 [Watson Pharmaceuticals Corona, California, USA], each mg daily) [4,5]. In one trial, the mean increase in total testosterone concentration from baseline was significantly greater in patients using Testim 1 Gel 100 mg, compared with Table 1 Clinical trials evaluating Testim 1 Gel 1% testosterone gel [2 6] Study No. of patients Age in years. Mean SD (range) Total testosterone at baseline in nmol/l. Mean SD a Design End-points Marbury et al. [2] (NR) b NR c Testim 1 Gel 50 mg vs. AndroGel 1 50 mg Pharmacokinetic profiles over 48 hours following a single administration Loizides et al. [3] (18 86) d Testim 1 Gel 50 mg or 100 mg Weekly assessment of sexual activity and mood over 1 month McNicholas et al. [4] (31 80) Testim 1 Gel 50 mg vs. Testim 1 Gel 100 mg vs. Andropatch mg Steidle et al. [5] Testim 1 Gel 50 mg vs. Testim 1 (20 80 included) e Gel 100 mg vs. Androderm 1 Dean et al. [6] (21 81 included) NR = not reported. a All patients were required to have total testosterone 10.4 nmol/l at baseline. b All patients were aged >45 years. c Total testosterone was <8.675 nmol/l in 19 patients and nmol/l in 10 patients at baseline. d 17.4% of patients were aged 65 years. e 26% of patients were aged 65 years. Pharmacokinetics, sexual activity, body composition, mood, and safety over 90 days Pharmacokinetics, sexual activity, body composition, mood, and safety over 90 days mg vs. placebo Testim 1 Gel 50 mg or 100 mg Pharmacokinetics, sexual activity, body composition, mood, and safety over 12 months
3 26 T.A. McNicholas / European Urology Supplements 4 (2005) Table 2 Changes in minimum, maximum, and average serum total testosterone levels (nmol/l) from baseline after 90 days of treatment with Testim 1 Gel or Andropatch 1 (n = 208) [4] Parameter Gel Patch 50 mg 100 mg DC avg a 3.82 DC min 2.98 b 7.14 a 0.35 DC max b 8.23 a p < vs. patch. b p < 0.05 vs. patch. those using patches (Table 2) [4]. Testim 1 Gel had similar dose-dependent effects on concentrations of DHT and free testosterone. Treatment with testosterone patches, however, produced relatively small changes in DHT concentrations (0.03 nmol/l for Andropatch 1, 0.91 nmol/l for Testim 1 Gel 50 mg, and 1.39 nmol/l for Testim 1 Gel 100 mg; p < for each comparison) [4]. Similar results were found in the second trial: after 90 days of treatment, 75 80% of patients receiving Testim 1 Gel had a mean serum concentration above the lower limit of normal (10.4 nmol/l), compared with 57% of patients treated with Androderm 1 patch and 10% of patients receiving placebo [5]. Openlabel extension studies of Testim 1 Gel following these two 90-day randomized trials indicated that increased serum levels of testosterone, DHT, and free testosterone were maintained for up to 12 months [6]. Given these data, it appears that Testim 1 Gel (50 mg or 100 mg daily) can effectively restore serum testosterone levels to within the normal range in men with hypogonadism [2,4 6]. Testim 1 Gel is not bioequivalent to another testosterone gel [2], and may have a more favourable pharmacokinetic profile compared with testosterone patches [4,5]. 3. Time to onset of effects To determine the time to response in sexual activity, desire, and mood following the initiation of treatment with Testim 1 Gel, the Study of Testosterone Androgen Response Time (START) was conducted [3]. A total of 638 men with hypogonadism were given Testim 1 Gel at a daily dose of 50 or 100 mg for 30 days. Each patient kept a validated self-report diary to collect information on sexual function and mood [7,8]. Beginning 1 week prior to treatment initiation, the diary continued through the 30-day treatment period and average weekly scores were calculated. The mean age of the men was 52.7 years (range: years) and 17.4% were aged 65 years. The mean morning serum testosterone concentration at baseline was 7.08 nmol/l. The percentage of patients who applied 1 tube of Testim 1 Gel daily was 89%. The remaining 11% started with 1 tube and increased to 2 tubes daily. By the end of the first week of treatment with Testim 1 Gel, scores for sexual desire, sexual motivation, spontaneous erections (day and night), sexual performance, sexual enjoyment, and satisfaction with duration of erection all increased significantly from baseline (Table 3) [3]. In general, maximum response was seen by the end of the second week and maintained throughout the study period [3].Significant improvements in the weekly frequency of intercourse were noted as early as week 2 [3]. Positive and negative mood scores also improved after treatment initiation, reached a maximum response within the first 2 weeks of treatment, and were maintained throughout the study [3]. Based on the results of the START study, it appears that improvement in sexual activity and mood can be seen within 2 weeks of initiating treatment with Testim 1 Gel [3]. The study investigators further suggested Table 3 Weekly scores of sexual function following initiation of Testim 1 Gel (N = 638) [3] Parameter Baseline Week 1 a Week 2 a Week 3 a Week 4 a Desire (0 = none, 7 = very high) Motivation (number of days/week) Performance (number of days/week) Enjoyment (0 = none, 7 = very high) With partner Without partner b Satisfaction with duration of erection (0 = not satisfied, 7 = very satisfied) Spontaneous erections (number of days/week) (Copyright# MedReviews, LLC. Reproduced with permission of MedReviews, LLC. Reviews in Urology is a copyrighted publication of MedReviews, LLC. All rights reserved.). Values are expressed as mean SD. a p < for all values versus baseline. b p < 0.01 versus baseline.
4 T.A. McNicholas / European Urology Supplements 4 (2005) that if clinicians do not see improvements within this time period, it may be necessary to check serum testosterone concentrations to determine whether dose adjustments are required [3]. 4. Short-term efficacy Two randomized, controlled trials (also discussed above in terms of their pharmacokinetic results) have evaluated the efficacy of Testim 1 Gel when given for 90 days (Table 4) [4,5]. Both trials compared the effects of Testim 1 Gel 50 mg or Testim 1 Gel 100 mg daily with those of testosterone patches (Androderm 1 or Andropatch 1, each mg daily) [4,5], and one of the trials included a placebo arm [5]. At day 30, 60, and 90, both trials measured mood and sexual function using a validated questionnaire [7,8] and body composition according to dual-energy X-ray absorptiometry (DEXA) [4,5] The European trial (McNicholas et al. [4]) A total of 208 men with hypogonadism were enrolled in a trial conducted in 29 centres in Denmark, Germany, the Netherlands, Sweden, and the UK [4]. The mean age was 57 years (range: years) and the mean serum concentration of testosterone at baseline was 7.92 nmol/l [4]. In all 3 treatment groups (Testim 1 Gel 50 mg, Testim 1 Gel 100 mg, Andropatch 1 ), scores for sexual function, including motivation, desire, and performance, improved after 90 days from baseline [4]. In both Testim 1 Gel groups, the incidence of spontaneous erections increased significantly at all time points from baseline, whereas there were no significant changes in the testosterone patch group (Table 4) [4]. Positive mood scores improved significantly from baseline at all time points in patients treated with Testim 1 Gel 50 mg or 100 mg, with the exception of scores on day 60 in the Testim 1 Gel 50 mg group [4]. In the testosterone patch group, positive mood scores were not significantly different from baseline at any time point, and differences among treatment groups were not statistically significant [4]. With regard to negative mood scores, however, patients who received Testim 1 Gel had significantly better scores after 90 days than those who received testosterone patches (p < 0.05) [4]. Negative mood scores improved significantly from baseline at all time points in patients treated with Testim 1 Gel 50 mg or 100 mg, with the exception of scores on day 30 in the Testim 1 Gel 100 mg group [4]. In patients who received testosterone patches, negative mood scores were not significantly different from baseline at any time point [4]. Lean body mass increased significantly from baseline in all 3 treatment groups [4]. The percent fat was reduced by 0.12% from baseline in the group receiving Testim 1 Gel 100 mg (p < 0.01) [4]. Because of the relatively short duration of the study, no significant changes in bone mineral density (BMD) were observed in any treatment group [4] The US trial (Steidle et al. [5]) Steidle et al. [5] reported the results of a randomized, placebo-controlled trial of 406 men with hypogonadism conducted at 43 centres in the USA. Men Table 4 Mean change from baseline to 90 days in scores for sexual function and body composition in 2 randomized, controlled trials [4,5] Parameter McNicholas et al. [4] (N = 208) Steidle et al. [5] (N = 406) Gel 50 mg Gel 100 mg Patch Gel 50 mg Gel 100 mg Patch Placebo Sexual function scores Desire (daily mean) a a b c a,d a a Motivation (weekly mean) b b b a,e b Performance (weekly mean) b a b a,e b b Spontaneous erections (weekly mean) b b a,f Body composition Lean body mass, kg b a b e,g Fat mass, kg d d d Percent fat, % b e d,g Values are expressed as mean SD. p < vs. baseline. p < 0.05 vs. baseline. p < 0.01 vs. baseline. p < 0.01 vs. placebo. p < 0.05 vs. placebo. p < vs. placebo. g p < 0.05 vs. patch.
5 28 T.A. McNicholas / European Urology Supplements 4 (2005) aged years were included, and 26% were aged 65 years [5]. The mean serum concentration of testosterone at baseline was 8.1 nmol/l [5]. Patients were given Testim 1 Gel 50 mg or 100 mg, Androderm 1, or placebo [5]. After 90 days, patients who received Testim 1 Gel 100 mg showed significant improvement in sexual motivation (p < 0.05), desire (p < 0.01), performance (p < 0.05), and the number of spontaneous erections (p < 0.001), compared with placebo [5]. Other measures of sexual function, such as enjoyment with or without a partner, satisfaction of erection duration, and percentage of full erection, revealed no significant differences between treatment groups [5]. Positive and negative mood scores improved from baseline in all treatment groups, and no statistical differences between treatment groups were found [5]. Lean body mass increased significantly in patients who received Testim 1 Gel 100 mg, compared with those who received testosterone patch or placebo (p < 0.05 for each comparison) [5]. Testim 1 Gel 50 mg and 100 mg significantly reduced fat mass and percent fat, compared with placebo (p < 0.05 and p < 0.01, respectively), whereas the testosterone patch did not [5]. The strikingly similar results reported in these 2 randomized, controlled trials confirm that, in men with hypogonadism, Testim 1 Gel can restore serum testosterone levels to within the normal range, leading to measurable improvements in sexual function, mood, and body composition [4,5]. The magnitude of benefit is similar to, or for some parameters, even better than that achieved with testosterone patches [4,5]. 5. Long-term efficacy The combined results of 2 studies which evaluated the long-term efficacy and safety of treatment with Testim 1 Gel were reported [6]. Patients who participated in both 90-day, randomized trials discussed above [4,5] were invited to enrol in an open-label, multicentre extension study, in which all patients received Testim 1 Gel (50 mg or 100 mg daily) for up to 12 months [6]. Of the combined 371 patients enrolled, 257 received Testim 1 Gel for >9 months [6]. Although all patients were hypogonadal when they entered the short-term studies [4,5], 90% had a baseline testosterone level within the normal range when they entered the long-term extension study [6]. Scores for sexual motivation, desire, and performance were significantly higher at all time points during the extension study, when compared with baseline scores (p < for each comparison) [6]. Satisfaction with Fig. 2. Positive and negative mood scores (on a 0 7 Likert-type categorical scale) during 12 months of treatment with Testim 1 Gel 50 mg or 100 mg, showing both dosage groups combined (N = 371) [6]. (Copyright# MedReviews, LLC. Reproduced with permission of MedReviews, LLC. Reviews in Urology is a copyrighted publication of MedReviews, LLC. All rights reserved.). the duration of erection, percentage of full erection, and the incidence of spontaneous erections also improved significantly. Improvements in positive and negative mood scores were seen as early as month 1 and were maintained throughout the study period (Fig. 2) [6]. Significant improvements in lean body mass, fat mass, and percent fat were seen at months 6 and 12 [6]. Total body mass, however, did not change significantly from baseline, according to DEXA scans [6]. BMD of the lumbar spine increased significantly from baseline (p < 0.001) [6]. The mean percent change from baseline in BMD was 1.33% at month 6 and 2.58% at month 12 (Fig. 3) [6]. Data from the long-term extension study support the conclusion that the improvements seen with Testim 1 Gel in the short-term randomized trials, including improvements in sexual function, mood, and body composition, were maintained for up to an additional Fig. 3. Mean percentage change in bone mineral density of the lumbar spine from baseline during 12 months of treatment with Testim 1 Gel 50 mg or 100 mg, showing both dosage groups combined (N = 371) [6]. (Copyright# MedReviews, LLC. Reproduced with permission of MedReviews, LLC. Reviews in Urology is a copyrighted publication of MedReviews, LLC. All rights reserved.).
6 T.A. McNicholas / European Urology Supplements 4 (2005) year of treatment [4 6]. Notably, the improvements in BMD suggest that continued treatment with Testim 1 Gel may provide ongoing bone repletion, which may prevent osteoporosis. 6. Tolerability In general, Testim 1 Gel is well tolerated and associated with few serious adverse events. In the two 90- day randomized studies, the total incidence of adverse events was similarly low in both Testim 1 Gel groups and substantially lower than that seen with testosterone patches [4,5]. This was due primarily to a lower rate of application-site reactions with the gel than with the patch [4,5]. The most common adverse events associated with Testim 1 Gel treatment are increases in haemoglobin and haematocrit levels, application-site reactions, and increases in prostate-specific antigen (PSA) levels [6]. Other less frequently reported side-effects include benign prostatic hyperplasia (BPH), increased blood pressure, acne, gynaecomastia, headache, hot flushes, insomnia, increased lacrimation, mood swings, smell and taste disorders, spontaneous erections, and reduced libido [5,6]. In the long-term extension study of Testim 1 Gel, 40 patients (10.8%) withdrew due to adverse events [6]. The most common reasons cited for study withdrawal were increases in PSA (2.4%), increases in haematology parameters (2.4%), and application-site reactions (1.1%) [6] Application-site reactions Local application-site reactions occurred in 4.0% and rash occurred in 1.9% of patients treated with Testim 1 Gel in the 12-month extension studies [6].In the two 90- day randomized trials comparing Testim 1 Gel and testosterone patches, the incidence and severity of application-site reactions were consistently higher in patients receiving testosterone patches, compared with those receiving Testim 1 Gel [4,5]. In both studies, approximately 15% of patients receiving testosterone patches withdrew from the study due to adverse events, mostly application-site reactions [4,5]. In the European trial, skin irritation occurred in 53% of patients using the testosterone patch for 90 days, compared with 4.2% and 0% of patients receiving Testim 1 Gel 100 mg and 50 mg, respectively [4]. Doubling the dose of Testim 1 Gel did not appear to increase the incidence or severity of skin reactions [4]. In the US study, the incidence of skin irritation among patients who received Testim 1 Gel was similar to the incidence in patients who received a placebo gel [5] Lipid profiles Small reductions in total cholesterol, HDL cholesterol, and LDL cholesterol have been reported with Testim 1 Gel treatment [4,5]. However, significant changes in the ratio of total:hdl cholesterol and of LDL:HDL cholesterol after 90 days of treatment, compared with baseline values, were not observed [4,5] Haematocrit and haemoglobin Increased testosterone levels are associated with increases in haematocrit and haemoglobin levels [5,9,10]. Therefore, as expected, treatment with Testim 1 Gel for 90 days was associated with an increase in haematocrit and haemoglobin levels, compared with baseline and placebo [4,5]. Testosterone patches also increased haematocrit and haemoglobin levels but to a lesser extent, reflecting the lower levels of serum testosterone achieved with patches [4,5]. In the US study, haematocrit and haemoglobin levels increased by % and g/dl, respectively, after 90 days of treatment with Testim 1 Gel 50 mg, and % and g/dl, respectively, with Testim 1 Gel 100 mg [5]. These increases were greater than those seen with patches ( % and g/dl) or placebo ( % and g/dl) [5].Inthe long-term extension study of Testim 1 Gel, mean values for haematocrit and haemoglobin increased but remained within the normal range throughout the 12- month study period [6]. Although a moderate increase in haematological parameters may be beneficial in some men with anaemia, lethargy, and fatigue, an increase in haematocrit to levels greater than 55% could produce symptoms of polycythaemia. Periodic monitoring of haematocrit and haemoglobin levels during treatment with Testim 1 Gel is therefore recommended Prostate health Testim 1 Gel is associated with moderate increases in PSA levels in some men. In the European trial, the percentage of patients who had a PSA value of >4.0 ng/ ml at least once during the study was 3%, 4%, and 3% in patients treated with Testim 1 Gel 50 mg, 100 mg, and testosterone patch, respectively [4]. The mean change in PSA values from baseline was <1.0 ng/ml in all treatment groups [4]. In the US trial, the percentage of patients who had a PSA value of >4.0 ng/ml at least once was 1.8%, 2.9%, 6.6%, and 3.2% in patients receiving Testim 1 Gel 50 mg, 100 mg, testosterone patch, and placebo, respectively [5]. The mean change in PSA values from baseline was 0.3, 0.1, 0.2, and 0.1 ng/ml, respectively [5]. In the long-term extension study of Testim 1 Gel, the mean increase in PSA
7 30 T.A. McNicholas / European Urology Supplements 4 (2005) level from baseline was small but statistically significant at 3, 6, and 9 months (0.39 ng/ml, 0.37 ng/ml, and 0.45 ng/ml, respectively; p < for each comparison) [6]. Mild BPH occurred in 3 patients in the US trial (2 of whom had received Testim 1 Gel and 1 had received placebo), and 2 patients in the testosterone patch group were diagnosed with prostate cancer [5]. In both 90- day trials, International Prostate Symptom Scores (IPSS) and results of digital rectal examinations (DRE) did not indicate any clinically relevant treatment-related effects or differences [4,5]. This was also seen in the long-term extension study of Testim 1 Gel, in which 3 patients (0.8%) were diagnosed with prostate cancer during the 12-month study period [6]. Given the incidence of prostate cancer in a general population of older men (<1%) [11], these occurrences were not unexpected. Nevertheless, patients undergoing testosterone substitution with Testim 1 Gel should be monitored regularly for changes in prostate health until data from longer-term studies on the effects of testosterone substitution on prostate health become available. 7. Conclusions For men with hypogonadism, Testim 1 Gel can effectively and consistently restore serum testosterone levels to within the normal range and may have a more favourable pharmacokinetic profile than another testosterone gel and testosterone patches [2,4,5]. Improvements in mood, sexual motivation, desire, and performance are seen within the first 2 weeks of initiating treatment, indicating that Testim 1 Gel can provide rapid improvements of some of the immediate symptoms of hypogonadism [3]. Data from randomized, controlled studies indicate that Testim 1 Gel is at least as effective as testosterone patches in improving mood, sexual function, and body composition, with the advantage of fewer application-site reactions [4,5]. Lastly, long-term data show that the benefits gained with Testim 1 Gel treatment are maintained for up to 12 months without a substantial increase in adverse events [6]. In patients who receive Testim 1 Gel, periodic monitoring of blood and prostate health by measuring haemoglobin, haematocrit, and PSA levels is necessary. References [1] Morales A, Lunenfeld B, for the International Society for the Study of the Aging Male. Investigation, treatment and monitoring of late-onset hypogonadism in males. Official recommendations of ISSAM. Aging Male 2002;5: [2] Marbury T, Hamill E, Bachand R, Sebree T, Smith T. Evaluation of the pharmacokinetic profiles of the new testosterone topical gel formulation, Testim TM, compared to AndroGel 1. Biopharm Drug Dispos 2003;24: [3] Loizides E, Swierzewski MJ, O Neill C, Griesser J, Smith T. Early response time in sexual activity and mood to testosterone gel replacement in hypogonadal males from the Testim 1 START study. Rev Urol 2004;6(Suppl 6):S [4] McNicholas TA, Dean JD, Mulder H, Carnegie C, Jones NA. A novel testosterone gel formulation normalizes androgen levels in hypogonadal men, with improvements in body composition and sexual function. BJU Int 2003;91: [5] Steidle C, Schwartz S, Jacoby K, Sebree T, Smith T, Bachand R, for the North American AA250 T Gel Study Group. AA2500 testosterone gel normalizes androgen levels in aging males with improvements in body composition and sexual function. J Clin Endocrinol Metab 2003;88: [6] Dean JD, Carnegie C, Rodzvilla J, Smith T. Long-term effects of Testim 1 1% testosterone gel in hypogonadal men. Rev Urol 2004;6(Suppl 6):S22 9. [7] Lee KK, Berman N, Alexander GM, Hull L, Swerdloff RS, Wang C. A simple self-report diary for assessing psychosexual function in hypogonadal men. J Androl 2003;24: [8] Arver S, Dobs AS, Meikle AW, Caramelli KE, Rajaram L, Sanders SW, et al. Long-term efficacy and safety of a permeation-enhanced testosterone transdermal system in hypogonadal men. Clin Endocrinol (Oxf) 1997;47: [9] Wang C, Swedloff R, Iranmanesh A, Dobs A, Snyder PJ, Cunningham G, et al., for the Testosterone Gel Study Group. Transdermal testosterone gel improves sexual function, mood, muscle strength, and body composition parameters in hypogonadal men. J Clin Endocrinol Metab 2000;85: [10] Tenover JL. Testosterone and the aging male. J Androl 1997;18: [11] Stanford JL, Stephenson RA, Coyle LM, Cerhan J, Correa R, Eley JW, et al. Prostate Cancer Trends, SEER Program, National Cancer Institute. NIH Pub. No Bethesda, MD, USA
Evaluation of the Pharmacokinetic Profiles of the New Testosterone Topical Gel Formulation, Testim TM, Compared to AndroGel 1
BIOPHARMACEUTICS & DRUG DISPOSITION Biopharm. Drug Dispos. 24: 115 120 (2003) Published online in Wiley InterScience (www.interscience.wiley.com). DOI: 10.1002/bdd.345 Evaluation of the Pharmacokinetic
More information6/14/2010. GnRH=Gonadotropin-Releasing Hormone.
Male Androgen Replacement Mitchell Sorsby, MD June 19, 2010. QUESTION # 1 Which of the following is not a symptom associated with low T levels? a) decreased libido b) erectile dysfunction c) depression
More informationCurrent Data and Considerations Novel Testosterone Formulations
Current Data and Considerations Novel Testosterone Formulations 1 Hypogonadism: Treatment Safety and Prostate Health 2 Monitoring for Testosterone Therapy DRE 1,2 PSA Parameter Voiding/IPSS 1,2 Hemoglobin
More informationEvaluation and Treatment of Primary Androgen Deficiency Syndrome in Male Patients
Evaluation and Treatment of Primary Androgen Deficiency Syndrome in Male Patients Jeff Unger, MD Director Chino Medical Group Diabetes and Headache Intervention Center Chino, California January 16, 2008
More informationAndroderm patch, AndroGel packets and pump, Axiron solution, First- Testosterone, First-Testosterone MC, Fortesta gel, Testim gel, Vogelxo
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.30.31 Subject: Testosterone Topical Page: 1 of 9 Last Review Date: September 23, 2016 Testosterone topical
More informationTestosterone Substitution and the Prostate
European Urology Supplements European Urology Supplements 4 (2005) 16 23 Testosterone Substitution and the Prostate E. David Crawford* University of Colorado Health Sciences Center, 1665 N. Ursula Street,
More informationManaging Testosterone Deficiency: A Practical Guide. John Grantmyre MD Professor of Urology Dalhousie University
Managing Testosterone Deficiency: A Practical Guide John Grantmyre MD Professor of Urology Dalhousie University 1 2 Case Study #1 A 59-Year-Old Man with Erectile Dysfunction 3 Case History Robert is a
More informationPoint-Counterpoint: Late Onset Hypogonadism (LOH)
Point-Counterpoint: Late Onset Hypogonadism (LOH) We are Under-diagnosing and Treating Men with LOH LOH is a Non-existent Disease ~ Robert E. Donohue, MD Late Onset Hypogonadism LOH: underdx. & undertx
More informationGUIDELINES ON. Introduction. G.R. Dohle, S. Arver, C. Bettocchi, S. Kliesch, M. Punab, W. de Ronde
GUIDELINES ON Male Hypogonadism G.R. Dohle, S. Arver,. Bettocchi, S. Kliesch, M. Punab, W. de Ronde Introduction Male hypogonadism is a clinical syndrome caused by androgen deficiency. It may adversely
More informationX/00/$03.00/0 Vol. 85, No. 8 The Journal of Clinical Endocrinology & Metabolism. Printed in U.S.A. Copyright 2000 by The Endocrine Society
0021-972X/00/$03.00/0 Vol. 85, No. 8 The Journal of Clinical Endocrinology & Metabolism Printed in U.S.A. Copyright 2000 by The Endocrine Society Transdermal Testosterone Gel Improves Sexual Function,
More informationTransdermal testosterone gel: pharmacokinetics, efficacy of dosing and application site in hypogonadal men
Original Article TRANSDERMAL TESTOSTERONE GEL A.W. MEIKLE et al. Testosterone gels are being increasingly used throughout the world. There is still some controversy associated with their use, but many
More informationTestosterone therapy in erectile dysfunction
The Aging Male 2004;7:312 318 Testosterone therapy in erectile dysfunction R. Department of Urology, Columbia University, New York, USA Key words: TESTOSTERONE, TESTOGEL 1, ERECTILE DYSFUNCTION, HYPOGONADISM,
More informationGUIDELINES ON MALE HYPOGONADISM
GUIDELINES ON MALE HYPOGONADISM (Text update March 2015) G.R. Dohle (Chair), S. Arver, C. Bettocchi, T.H. Jones, S. Kliesch, M. Punab Introduction Male hypogonadism is a clinical syndrome caused by androgen
More informationLate onset Hypogonadism. Dr KhooSay Chuan Department of Urology Penang General Hospital
Late onset Hypogonadism Dr KhooSay Chuan Department of Urology Penang General Hospital Late onset hypogonadism(loh) Definition LOH age associated testoteronedeficiency syndrome (TDS) Male menopause, andropause,
More informationEAU GUIDELINES ON MALE HYPOGONADISM
EAU GUIDELINES ON MALE HYPOGONADISM (Text update March 2015) G.R. Dohle (Chair), S. Arver, C. Bettocchi, T.H. Jones, S. Kliesch, M. Punab Introduction Male hypogonadism is a clinical syndrome caused by
More informationAndrogens. Medication Strengths Quantity Limit Comments Androderm (testosterone patch) 1% pump 2 pump bottles per Non-Preferred
Market DC Androgens Override(s) Prior Authorization Quantity Limit Approval Duration Varies upon diagnosis Medication Strengths Quantity Limit Comments Androderm (testosterone patch) AndroGel (testosterone
More informationHypogonadism 4/27/2018. Male Hypogonadism -- Definition. Epidemiology. Objectives HYPOGONADISM. Men with Hypogonadism. 95% untreated.
Male Hypogonadism -- Definition - Low T, Low Testosterone Hypogonadism -...a clinical syndrome that results from failure of the testes to produce physiological concentrations of testosterone due to pathology
More informationHYPOGONADISM DEFINITION: PRODUCTION OF SEX HORMONES AND GERM CELLS IS INADEQUATE (ENDOCRINE SOCIETY)
HYPOGONADISM DEFINITION: PRODUCTION OF SEX HORMONES AND GERM CELLS IS INADEQUATE (ENDOCRINE SOCIETY) DEFECT OF THE REPRODUCTIVE SYSTEM THAT RESULTS IN LACK OF FUNCTION OF THE GONADS (Wikipedia) REDUCTION
More informationDepartment of Urology, Case Western Reserve University, University Hospitals of Cleveland, Cleveland, OH, USA
(2007) 19, 2 24 & 2007 Nature Publishing Group All rights reserved 0955-9930/07 $30.00 www.nature.com/ijir REVIEW for male hypogonadism: Part III. Pharmacologic and clinical profiles, monitoring, safety
More informationClinical Policy: Testosterone Pellet (Testopel) Reference Number: CP.CPA.## [Pre-P&T approval] Effective Date:
Clinical Policy: (Testopel) Reference Number: CP.CPA.## [Pre-P&T approval] Effective Date: 07.25.17 Last Review Date: 11.17 Line of Business: Commercial Coding Implications Revision Log See Important Reminder
More informationHow to treat: TRT modalities and formulations
How to treat: TRT modalities and formulations Paul PIETTE, PharmD Senior Research Fellow Clinique Antoine Depage - Belgium ppiette@besins-healthcare.com Bruges 2014, May 15 th Testosterone-replacement
More informationA dro r gen e R e R p e lac a e c m e e m n e t t T her e a r p a y Androgen Replacement Therapy in the Aging O j b ecti t ve v s Male
Androgen Replacement Therapy in the Aging Male Thomas J. Walsh, MD, MS Department of Urology University of California, San Francisco Objectives 1. List 3 effects of androgens on normal male physiology.
More informationGA KS KY LA MD NJ NV NY TN TX WA Applicable X X N/A N/A X N/A X X X X X X N/A N/A NA *FHK- Florida Healthy Kids. Androgens
Androgens Override(s) Prior Authorization Quantity Limit Approval Duration Varies upon diagnosis Medication Strengths Quantity Limit Comments Generic Androgel 1% (2.5 g) packet 2 packets per day (testosterone
More informationAbstract and Introduction. Topical/transdermal Therapies
www.medscape.com Testosterone Replacement Therapy for Male Hypogonadism: Part III. Pharmacologic and Clinical Profiles, Monitoring, Safety Issues, and Potential Future Agents A Seftel Int J Impot Res.
More informationCigna Drug and Biologic Coverage Policy
Cigna Drug and Biologic Coverage Policy Subject Testosterone Therapy Table of Contents Coverage Policy... 1 General Background... 6 Coding/Billing Information... 7 References... 7 Effective Date... 1/1/2018
More informationPeter J. Burrows MD FACS
Testosterone Supplementation, Prostate Cancer Screening and Vitamins Peter J. Burrows MD FACS Clinical Assistant Professor of Urology University of Arizona, College of Medicine Adjunct Assistant Professor
More informationPharmacy Coverage Guidelines are subject to change as new information becomes available.
TESTOSTERONE REPLACEMENT THERAPY: ANDRODERM transdermal patch ANDROGEL pump transdermal gel and transdermal gel AXIRON transdermal solution FORTESTA transdermal gel NATESTO nasal gel STRIANT buccal mucoadhesive
More informationHormone Replacement Therapy For Men Consultation Information
Hormone Replacement Therapy For Men Consultation Information www.urologyaustin.com Biological Aging and Hormones As we age, a natural degeneration and aging of organs causes the levels of our hormones
More informationCorporate Medical Policy Testosterone Pellet Implantation for Androgen Deficiency
Corporate Medical Policy Testosterone Pellet Implantation for Androgen Deficiency File Name: Origination: Last CAP Review: Next CAP Review: Last Review: testosterone_pellet_implantation_for_androgen_deficiency
More informationTestosterone (cypionate, enanthate, and propionate) powder, Fluoxymesterone powder, Methyltestosterone powder
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.08.37 Subject: Testosterone Powder Page: 1 of 11 Last Review Date: September 18, 2015 Testosterone powder
More informationEAU GUIDELINES ON MALE HYPOGONADISM
EAU GUIDELINES ON MALE HYPOGONADISM (Limited text update March 2017) G.R. Dohle (Chair), S. Arver, C. Bettocchi, T.H. Jones, S. Kliesch Introduction Male hypogonadism is a clinical syndrome caused by androgen
More informationANDROGEL 50 mg, gel in sachet Testosterone
Read all of this leaflet carefully before you start using this medicine because it contains important information for you. - Keep this leaflet. You may need to read it again. - If you have any further
More informationMale Hypogonadism. Types and causes of hypogonadism. What is male hypogonadism? Symptoms. Testosterone production. Patient Information.
Patient Information English 31 Male Hypogonadism The underlined terms are listed in the glossary. What is male hypogonadism? Male hypogonadism means the testicles do not produce enough of the male sex
More informationIncreasing Awareness, Diagnosis, and Treatment of BPH, LUTS, and EP
Introduction to Enlarged Prostate E. David Crawford, MD Professor of Surgery (Urology) and Radiation Oncology Head, Urologic Oncology E. David Crawford Endowed Chair in Urologic Oncology University of
More informationTestosterone Therapy and the Prostate. Frans M.J. Debruyne Professor of Urology The Netherlands
Testosterone Therapy and the Prostate Frans M.J. Debruyne Professor of Urology The Netherlands TRT- Risks Prostate ( Cancer, BPH )? Cardiac? Lipids? Polycythemia Sleep apnea Gynecomastia Edema Testosterone
More informationDisclosures. Dr. Swerdloff and/or Dr. Wang have served as. o Consultants: Abbvie, Novartis, Clarus, AEZ, Lipocine, Antares Pharma
Safety and Efficacy Results From the Phase-3, Double-Blind, Multicenter STEADY Trial of a Novel, Pre-Filled, Subcutaneous Auto-Injector For Testosterone Replacement Therapy Ronald Swerdloff, MD Harbor
More information/04/ /0 Reprinted from Vol. 172, , August 2004 THE JOURNAL OF UROLOGY
0022-5347/04/1722-0658/0 Reprinted from Vol. 172, 658 663, August 2004 THE JOURNAL OF UROLOGY Printed in U.S.A. Copyright 2004 by AMERICAN UROLOGICAL ASSOCIATION DOI: 10.1097/01.ju.0000132389.97804.d7
More informationWhat Is the Low T Syndrome? Is Testosterone Supplementation Safe?
What Is the Low T Syndrome? Is Testosterone Supplementation Safe? UCSF Osher Mini Medical School March 7, 2018 Dolores Shoback, MD Staff Physician SF-VAMC Professor of Medicine, UCSF No disclosures or
More informationTestosterone Oral Buccal Nasal. Android, Androxy, Methitest, Natesto, Striant, Testred. Description
1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.30.32 Subject: Testosterone Oral Buccal Nasal Page: 1 of 10 Last Review Date: March 17, 2017 Testosterone Oral Buccal Nasal Description
More informationJuly 2006 (NASDAQ: AUXL)
July 2006 (NASDAQ: AUXL) Safe Harbor Statement We will make various remarks during this presentation that constitute forward-looking statements for purposes of the safe harbor provisions under The Private
More informationTestosterone Oral Buccal Nasal. Android, Androxy, Methitest, Natesto, Striant, Testred. Description
1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.30.32 Subject: Testosterone Oral Buccal Nasal Page: 1 of 10 Last Review Date: November 30, 2018 Testosterone Oral Buccal Nasal
More informationTestosterone Replacement Therapy for Hypogonadism: Learning Objectives. What Is the Evidence? Is It Safe? Case Study. Case Study contd.
4 4:4pm Testosterone Therapy: Examining the Evidence SPEAKER Culley Carson, MD Presenter Disclosure Information The following relationships exist related to this presentation: Culley Carson, MD: Consultant
More informationLate onset hypogonadism
Late onset hypogonadism Farrukh Javid Male Menopause Clinical AND biochemical syndrome Testosterone levels decline by 0.4-3% per year after the age of 30, as opposed to the more rapid decline that occurs
More informationTestosterone (cypionate, enanthate, and propionate) powder, Fluoxymesterone powder, Methyltestosterone powder
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.30.37 Subject: Testosterone Powder Page: 1 of 12 Last Review Date: November 30, 2018 Testosterone powder
More informationPrescribing Framework for Testosterone in Adults
Prescribing Framework for Testosterone in Adults Patient s Name:.. NHS Number: Patient s Address:... (Use addressograph sticker) GP s Name:... Communication We agree to treat this patient within this Prescribing
More informationHypogonadism in Men. CME Away India & Sri Lanka March 23 - April 7, 2018
Hypogonadism in Men CME Away India & Sri Lanka March 23 - April 7, 2018 Richard A. Bebb MD, ABIM, FRCPC Consultant Endocrinologist Medical Subspecialty Institute Cleveland Clinic Abu Dhabi Copyright 2017
More informationX/99/$03.00/0 Vol. 84, No. 10 The Journal of Clinical Endocrinology & Metabolism Copyright 1999 by The Endocrine Society
0021-972X/99/$03.00/0 Vol. 84, No. 10 The Journal of Clinical Endocrinology & Metabolism Printed in U.S.A. Copyright 1999 by The Endocrine Society Pharmacokinetics, Efficacy, and Safety of a Permeation-
More informationPRISM Bruges June Herman Leliefeld Urologist. The Netherlands
PRISM Bruges 25-26 June 2015 Herman Leliefeld Urologist The Netherlands Guidelines EAU 2015: a rich source of Knowledge! Epidemiology/ Aetiology / Pathology Diagnostic evaluation Disease management Follow-Up
More informationAn Evidence-based Review of Clinical Trial Data
An Evidence-based Review of Clinical Trial Data Karen K. Miller, MD Massachusetts General Hospital Harvard Medical School Boston, MA 1 Rationale for Investigating Androgen Administration in Women: Data
More informationPARTICIPANT INFORMATION & CONSENT FORM
PARTICIPANT INFORMATION & CONSENT FORM Version 2.2 dated 19 August 2015 Study Title: A 2-year, multi-centre double-blind, randomised, placebo-controlled trial to determine in men with total testosterone
More informationPreparing for the road ahead. LEARN MORE ABOUT these 5 risks
Preparing for the road ahead LEARN MORE ABOUT these 5 risks to A MAN S health 3 4 5 2 6 1 7 0 8 9 WHY DOES IT SEEM LIKE SOME MEN TAKE BETTER CARE OF THEIR CARS THAN THEIR OWN HEALTH? When the check engine
More informationOver the past decade, androgen replacement
J. Andrew Hoover, MD; Jeffrey T. Kirchner, DO, FAAFP Department of Family and Community Medicine, Lancaster General Hospital, Pa jhoover4@lghealth.org The authors reported no potential conflict of interest
More informationPharmacy Coverage Guidelines are subject to change as new information becomes available.
TESTOSTERONE REPLACEMENT THERAPY: ANDRODERM transdermal patch ANDROGEL pump transdermal gel and transdermal gel ANDROID (methyltestosterone) oral capsule ANDROXY (fluoxymesterone) oral tablet AXIRON transdermal
More informationTestosterone Therapy in Men with Hypogonadism
Testosterone Therapy in Men with Hypogonadism (Endocrine Society 2018 Guideline) Ngwe Yin, MD Assistant Clinical Professor of Medicine, UCSF Fresno Medical Education Program Disclosures None Objective
More information2. What you need to know before you use TESTOGEL
TESTOGEL 50 mg, gel in sachet Testosterone Read all of this leaflet carefully before you start using this medicine because it contains important information for you. - Keep this leaflet. You may need to
More informationRecognizing and Managing Testosterone Deficiency
Recognizing and Managing Testosterone Deficiency J. Bruce Redmon, M.D. Professor Division of Endocrinology Departments of Medicine and Urologic Surgery Disclosure Information I have no financial relationships
More informationRecommendations on the diagnosis, treatment and monitoring of Testosterone deficiency (TD) in adult men
Recommendations on the diagnosis, treatment and monitoring of Testosterone deficiency (TD) in adult men Bruno Lunenfeld, George Mskhalaya, Svetlana Kalinchenko, Yulia Tishova, Michael Zitzmann, Stefan
More informationTestosterone Oral Buccal Nasal. Android, Androxy, Methitest, Natesto, Striant, Testred. Description
1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.30.32 Subject: Testosterone Oral Buccal Nasal Page: 1 of 10 Last Review Date: June 24, 2016 Testosterone Oral Buccal Nasal Description
More informationISSM QUICK REFERENCE GUIDE ON TESTOSTERONE DEFICIENCY FOR MEN
International Society for Sexual Medicine - www.issm.info ISSM QUICK REFERENCE GUIDE ON TESTOSTERONE DEFICIENCY FOR MEN Version: September 2015 What is testosterone deficiency? Testosterone deficiency
More informationConsent for Testosterone Therapy-Men Revised 4/10/18
Consent for Testosterone Therapy in Men You have been diagnosed with or have an increased risk of having a hormone deficiency and your provider has recommended treatment with bio-identical hormone replacement
More informationMale Menopause: Disease or Pseudoscience? March 4, 2015 story: FDA to require warning on labels of testosterone products.
Male Menopause: Disease or Pseudoscience? March 4, 2015 story: FDA to require warning on labels of testosterone products. 3-30-2015; web William E. Winter, MD University of Florida Departments of Pathology
More informationEndocrine Update Mary T. Korytkowski MD Division of Endocrinology University of Pittsburgh
Endocrine Update 2016 Mary T. Korytkowski MD Division of Endocrinology University of Pittsburgh Disclosure of Financial Relationships Mary Korytkowski MD Honoraria British Medical Journal Diabetes Research
More informationTestosterone supplementation in the aging male: Which questions have been answered?
The Aging Male, March 2005; 8(1): 31 38 Testosterone supplementation in the aging male: Which questions have been answered? WALTER KRAUSE 1, ULRICH MUELLER 2, & ALLAN MAZUR 3 1 Department of Andrology,
More informationTESTOSTERONE REPLACEMENT THERAPY
TESTOSTERONE REPLACEMENT THERAPY Testosterone is the hormone responsible for the normal growth and development of the male sex organs and for maintenance of secondary sex characteristics. These include
More informationTestosterone Injection / Implant
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Testosterone Injection / Implant Page: 1 of 9 Last Review Date: December 5, 2014 Testosterone
More informationAndrogen deficiency. Dr Rakesh Iyer Staff Specialist in Endocrinology Calvary hospital
Androgen deficiency Dr Rakesh Iyer Staff Specialist in Endocrinology Calvary hospital Outline Pathological androgen deficiency - Background, causes, interpretation - Indications for treatment Androgen
More informationTestosterone Therapy in Men An update
Testosterone Therapy in Men An update SANDEEP DHINDSA Associate Professor of Medicine Director, Division of Endocrinology and Metabolism, Saint Louis University, St. Louis, MO Presenter Disclosure None
More informationTestosterone Injection and Implant
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.30.33 Subject: Testosterone Injection Implant Page: 1 of 10 Last Review Date: December 8, 2017 Testosterone
More informationTRT and localized protate cancer
TRT and localized protate cancer Frans M. J. Debruyne Professor of Urology PRISM BRUGES Increased risk of prostate cancer with TRT? Prostate cancer Testosterone and Prostate Cancer There appears to be
More informationTEST REPORT # SB. Patient Name: Comprehensive Male Profile I Patient Phone Number: TEST NAME RESULTS 08/12/18 RANGE
TEST REPORT Ordering Provider: David Getuwell, MD 8605 SW Creekside Place Beaverton, OR 97008 Phone: 503-466-2445 Fax: 503-466-1636 Samples Received 08/15/2018 Report Date 08/20/2018 Samples Collected
More informationExperience with transdermal testosterone replacement therapy for hypogonadal men
Clinical Endocrinology (1999) 50, 57 62 Experience with transdermal testosterone replacement therapy for hypogonadal men Susan Parker and Mary Armitage Diabetes and Endocrine Unit, Royal ournemouth Hospital,
More informationImplantable Hormone Pellets
Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc.(collectively referred to as the Company ), unless otherwise provided
More informationThe reality of LOH-symptoms
The reality of LOH-symptoms PRISM IV Bruges, Belgium September 25-26, 2014 Dr. Herman Leliefeld Androsmannenkliniek The Netherlands The reality of LOH symptoms male external & internal genitalia Testosterone
More informationComparison of Testosterone Replacement Therapy Medications for Treatment of Hypogonadism
Brigham Young University BYU ScholarsArchive All Faculty Publications 2017-01-27 Comparison of Testosterone Replacement Therapy Medications for Treatment of Hypogonadism Karlen Beth Luthy Brigham Young
More informationHypogonadism and Testosterone Replacement Therapy: Pharmacist
Hypogonadism and Testosterone Replacement Therapy: Practical Insights for the Pharmacist Roger G. Hefflinger, PharmD Associate Professor of Pharmacy Practice and Administrative Services Idaho State University,
More informationTestosterone Replacement in Adults. John A. Seibel, MD, FACP, MACE
Testosterone Replacement in Adults John A. Seibel, MD, FACP, MACE Disclosures None! *Privately Authenticated Definition of Male Hypogonadism inadequate gonadal function, as manifested by deficiencies in
More informationTestosterone Injection and Implant
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.30.33 Subject: Testosterone Injection Implant Page: 1 of 10 Last Review Date: March 17, 2017 Testosterone
More informationTestosterone Replacement Therapy and Prostate Cancer Incidence
pissn: 2287-4208 / eissn: 2287-4690 World J Mens Health 2015 December 33(3): 125-129 http://dx.doi.org/10.5534/wjmh.2015.33.3.125 Review Article Testosterone Replacement Therapy and Prostate Cancer Incidence
More informationHIGHLIGHTS. From Testosterone Update Disease State Theater. American Urological Association and Endocrine Society Annual Meetings
HIGHLIGHTS From Testosterone Update Disease State Theater Presentations held at the 2008 American Urological Association and Endocrine Society Annual Meetings Jointly sponsored by the Annenberg Center
More informationThe Impact of Premature Ejaculation on Partners and Relationships
available at www.sciencedirect.com journal homepage: www.europeanurology.com The Impact of Premature Ejaculation on Partners and Relationships Tricia Barnes * 90 Harley Street, London W1G 7HS, United Kingdom
More informationGP guide to testosterone replacement therapy in men
GP guide to testosterone replacement therapy in men SPL Mike Kirby FRCP Professor Mike Kirby describes how the diagnosis and treatment of test - osterone deficiency in primary care can lead to improved
More information25 mg oestradiol implants--the dosage of first choice for subcutaneous oestrogen replacement therapy?
Research Subcutaneous estrogen replacement therapy. Jones SC. Journal of Reproductive Medicine March, 2004; 49(3):139-142. Department of Obstetrics and Gynecology, Keesler Medical Center, Keesler Air Force
More informationThe Centre for Men s Health
96 Harley Street (London) and Manchester All Enquiries - +44 (0)20 7486 2277 www.centreformenshealth.co.uk/ This leaflet provides information about: The Centre for Men s Health The conditions we treat:
More information10 Novel Testosterone Formulations and Dosing: Potential Impact on Treatment and Outcomes Ajay Nehra, MD
VOLUME 1 NUMBER 1 MAY 30, 2008 1 Letter From the Co-Chairs Glenn R. Cunningham, MD, and Ridwan Shabsigh, MD 2 CME Accreditation Information 4 Introduction 4 Epidemiology of Hypogonadism Glenn R. Cunningham,
More informationpresents with Ken Sekine, MD
presents Pioneering Technologies For Pellet Hormone Therapy Lifestyle Based Medicine A Primer for Clinicians with Ken Sekine, MD Dr. Sekine is a board certified OB-GYN who has been in private practice
More informationLong-Term Pharmacokinetics and Clinical Efficacy of Andromen Forte 5% Cream for Androgen Replacement Therapy in Hypogonadal Men. Final Study Report
Long-Term Pharmacokinetics and Clinical Efficacy of Andromen Forte 5% Cream for Androgen Replacement Therapy in Hypogonadal Men Final Study Report Principal Investigator: Professor DJ Handelsman Centre
More informationENDOCRINOLOGICAL IMPLICATIONS AND COMPLICATIONS OF TESTOSTERONE REPLACEMENT IN AGEING MEN
ENDOCRINOLOGICAL IMPLICATIONS AND COMPLICATIONS OF TESTOSTERONE REPLACEMENT IN AGEING MEN Frederick C.W. Wu Professor of Medicine and Endocrinology Andrology Research Unit, Centre for Endocrinology and
More informationGH Replacement Therapy in Growth Hormone Deficient Adults
GH Replacement Therapy in Growth Hormone Deficient Adults Sequence of hormone loss in hypopituitarism depending on location of a benign tumor Besser GM, Cudworth AG, eds. Clinical endocrinology: an illustrated
More informationMetastatic disease. 80% will die of prostate cancer 5 year survival only 25% No major advances in cure since 1942
Prostate cancer Metastatic disease 80% will die of prostate cancer 5 year survival only 25% No major advances in cure since 1942 Impact of early prostate cancer 12 10 8 6 4 2 0 70-80 years 60-70 years
More informationIndex. urologic.theclinics.com. Note: Page numbers of article titles are in boldface type.
Note: Page numbers of article titles are in boldface type. A Acquired hypogonadism, prevalence of, 165 167 primary, 165 secondary, 167 Adipose tissue, as an organ, 240 241 Adrenal hyperplasia, congenital,
More informationTestosterone Injection and Implant
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.30.33 Subject: Testosterone Injection Implant Page: 1 of 10 Last Review Date: November 30, 2018 Testosterone
More informationInformation About Hormonal Treatment for Trans men
Information About Hormonal Treatment for Trans men Leighton J Seal PhD FRCP Consultant Endocrinologist, Gender Identity Clinic, (Charing Cross) West London Mental Health NHS Trust 12/12/2016 Introduction...
More informationAn Idea Whose Time Has Come-Male Health Programs: An Opportunity For Clinical Expansion and Better Health
An Idea Whose Time Has Come-Male Health Programs: An Opportunity For Clinical Expansion and Better Health KEVIN R. LOUGHLIN MD,MBA Harvard Medical School Boston, MA THE WEAKER SEX-MALES LIFE EXPECTANCY
More informationTHE RELEVANCE OF TESTOSTERONE THERAPY IN MANAGING PATIENTS WITH ERECTILE DYSFUNCTION
THE RELEVANCE OF TESTOSTERONE THERAPY IN MANAGING PATIENTS WITH ERECTILE DYSFUNCTION Aksam A. Yassin MD PhD EdD FEBU Professor of Urology & Human Sexuality Institute of Urology & Andrology, Segeberger
More informationDoes TRT Induce Prostate Cancer?
Does TRT Induce Prostate Cancer? Prism VI, Bruges, Belgium 21-22November 2014 Herman Leliefeld, Urologist, Utrecht The Netherlands Does TRT Induce Prostate Cancer? Why is it a controversial topic? Is there
More informationA USER S GUIDE WHAT EVERY MAN NEEDS TO KNOW
A USER S GUIDE WHAT EVERY MAN NEEDS TO KNOW 1. Why men need to know more Good health is vital for a happy and full life. But, with work and family responsibilities, men often overlook their own health
More informationMen s Health Hormone Self-Assessment
Page 1 of 5 12/2016 Consulting Pharmacist: _Consultation Date: How did you hear about College Pharmacy s & Consultation Services? Advertisement Another Patient Healthcare Provider Books/Articles Website
More informationCERTIFIED MEN S HEALTH COUNSELOR ONLINE COURSE: SESSION 7 Male Menopause and Testosterone
CERTIFIED MEN S HEALTH COUNSELOR ONLINE COURSE: SESSION 7 Male Menopause and Testosterone Andropause: Dealing With Male Menopause Hormonal changes that occur as a result of aging are generally associated
More informationPRNRX COMPOUNDING PHARMACY
Male Patient Health History Form Complete the following form and mail to: PRNRx LLC, 17755 W. Liberty Lane, New Berlin, WI 53146 Or fax to: 1-855-957-7679 or email to: MichelleK@prnrx.com To provide your
More information- Linzagolix overall efficacy and safety maintained or improved at week 24
Final results of ObsEva SA Phase 2b EDELWEISS trial of Linzagolix show sustained efficacy and Bone Mineral Density safety, for the treatment of endometriosis-associated pain - Linzagolix overall efficacy
More information